Recro Pharma
Malvern
About Recro Pharma
Recro Pharma is a clinical-stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting. The company's lead product, an intranasal formulation of Dexmedetomidine, or Dex, has completed a Phase Ib placebo-controlled trial demonstrating pain relief. It was founded in 2007 and headquartered in Malvern, Pennsylvania.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $50K – $100K
- Total funding: $274.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Aug 2023)
- Ticker: nasdaq:SCTL
- Website: recropharma.com
- Phone: (484) 395-2400
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/recro-pharma-136950 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.